Stryker, Osiris partner for new products; Kew Group raises $18.8M;

@FierceMedDev: ICYMI yesterday: Asante files for $45M IPO to market cheap, easy insulin pump. More | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ interview comments: NIH launches crowdsourcing challenge to commercialize its neurological medical devices. Report | Follow @VarunSaxena2

@EmilyWFierce: Check out @FierceBiotech's latest special report for this year's biotech winners and losers. More | Follow @EmilyWFierce

> Genomic cancer diagnostics company Kew Group has raised $16.8 million from 40 investors. SEC filing

> Regenerative medicine company Osiris Therapeutics ($OSIR) has partnered with Stryker ($SYK) to develop and market wound care, orthopedics and sports medicine products. Terms of the deal were undisclosed. Release

> Beleaguered micro-cap Echo Therapeutics ($ECTE), which has a noninvasive, wireless blood glucose monitor, has come to an agreement with activist investor Platinum Partners. Three board members will depart under the deal and the company is getting a $4 million investment from its largest shareholder. Story

Biotech News

@FierceBiotech: New special report: Best and worst 2014 biotech performers on Wall Street. Feature | Follow @FierceBiotech

@JohnCFierce: Astellas adds to deal spree with expanded $675M-plus Cytokinetics pact. Article | Follow @JohnCFierce

@DamianFierce: $ABBV's Viekira pitch includes this boomer-focused quiz thing on Facebook, featuring rotary phones and candy paper. More | Follow @DamianFierce

> J&J inks an antibody discovery deal with Sevion. Item

> Vanda settles its squabble with Novartis and pockets $25M for its trouble. Story

> Medivation buys into PD-1, picking up where Teva left off. Article

> Ariad flips Iclusig's Asian rights to Otsuka for $77.5M-plus. Report

Pharma News

@FiercePharma: Pfizer turns the sex talk toward 50-ish women with menopause awareness push. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Cubist has its Zerbaxa OK. Can Merck make the launch justify its $9.5B buyout? Article | Follow @CarlyHFierce

> With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda. More

> Justice Department sues Omnicare for rigging kickbacks with Abbott. Report

> Want to place biopharma bets for 2015? JPM flags Alexion, BioMarin and Bristol-Myers. Article

> SEC says insider made $10M on Abbott, CFR deal. Story

Biotech Research News

> Northwestern team claims they have found the right way to ID Alzheimer's early on. Report

> New research points to a key driver--and new drug target--behind hepatitis infections. More

> Brown U dean points to a possible suspect driving metastasis. Article

> Stem cell investigator resigns in wake of controversy. Item

> J&J, Lundbeck spearhead an R&D consortium focused on depression, neurodegeneration. Story

Pharma Manufacturing News

> Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax. Item

> Bayer picks Cardinal Health to manufacture Xofigo in U.S. News

> Fujifilm becomes part of U.S. pandemic defense with deal for Kalon Biotherapeutics. More

> India warns Egyptian companies claiming to have Sovaldi for sale. Article

> Fresenius closes out recall started two years ago. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.